Scientists create technology that measures tumors' drug resistance up to 10 times faster

April 16, 2018, Virginia Commonwealth University
HLSCI image of live melanoma cells colored to indicate the distribution of mass within each cell. Credit: VCU Massey Cancer Center

A group of scientists from VCU Massey Cancer Center and UCLA Jonsson Comprehensive Cancer Center have developed a new, high-speed microscopy platform that can measure a cancer cell's resistance to drugs up to 10 times faster than existing technology, potentially informing more effective treatment selection for cancer patients. The technology is being presented in abstract form today at the American Association for Cancer Research's Annual Meeting in Chicago.

Fast and repeated assessments of tumor sensitivity to available drugs can improve clinical outcomes by staying ahead of a 's ability to resist certain therapies.

Quantitative phase imaging has proven to be effective in measuring individual cell growth in response to various therapies, especially in cancers that grow in clusters such as melanoma. However, in current implementations, this technique is constrained by limited sample size.

The group of scientists led by Jason Reed, Ph.D., member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center, created a novel multi-sample, multidrug testing platform called High-Speed Live-Cell Interferometry (HSLCI) that directly measures tumor response to at a significantly accelerated rate.

HSLCI closely monitors the growth of a single cell's mass over time, but can measure the individual growth of 1,000 to 10,000 cells in one experiment, compared to previous studies which were limited to the analysis of approximately 60 cells per hour. If HSLCI measures a decrease in the growth of cancer cells, this is a sign that a treatment is effective.

"Our platform can detect effective versus ineffective drugs in patient-derived cells in a matter of hours, more than 10 times faster than the current standard. This speed and accuracy make HSLCI the first implementation of quantitative phase microscopy with the throughput required for a tool to guide patient therapy selection," said Kevin Leslie, M.S., a lead author of the study and PhD candidate in VCU's Integrative Life Sciences program.

Leslie added that HSLCI can track cell behavior for more than five days, compared to a maximum duration of 48 hours common to most previous research.

In a study, published in Analytical Chemistry, Reed applied HSLCI to models of metastatic melanoma, a disease in which tumor diversity and drug resistance are substantial obstacles to improved patient outcomes. Up to 80 percent of advanced melanoma patients receiving combination therapy develop drug resistance upon treatment.

There are presently no reliable cellular biomarkers that can guide targeted melanoma therapy or improve patient outcome predictions, and measuring drug response in vitro (in cells removed from the organism) often requires long turnaround times.

"A superior, rapid, accurate and inexpensive approach to determine melanoma drug sensitivity before - and periodically during - therapy is desirable," said Reed, an associate professor of physics at Virginia Commonwealth University.

Using industrial-grade imaging hardware, low-cost, multi-core PC processors and additional software improvements, Reed designed a completely new platform to combat these inefficiencies. The HSLCI takes images of standard-format, multi-well cell culture plates where each well can hold a different cell type exposed to a unique drug dose or combination. Requiring no fluorescence or dye labeling, it is well-equipped for noninvasive measurements of single cells and cell clusters.

Reed's research found that HSLCI successfully differentiated between thousands of drug-sensitive and -resistant melanoma in 24 hours.

"HSLCI could be used throughout all forms of cancer therapy to evaluate the efficacy of treatment. This assessment could ensure all are receiving the most effective drugs for their disease," Reed said.

Reed hopes he can further develop this technology in preclinical animal tests and early-phase clinical trials, using breast cancer models in collaboration with Chuck Harrell, Ph.D., a member of Massey's Cancer Molecular Genetics research program.

Explore further: Discovery of four subtypes of melanoma points to new treatment approaches

Related Stories

Discovery of four subtypes of melanoma points to new treatment approaches

April 12, 2018
Melanoma, a relatively rare but deadly skin cancer, has been shown to switch differentiation states—that is, to regress to an earlier stage of development—which can lead it to become resistant to treatment. Now, UCLA ...

'Idling' cancer cells may return

April 12, 2018
About half of all melanomas have mutations in the BRAF gene that accelerate tumor cell growth and spread. While most patients benefit from targeted anti-BRAF therapy, resistance to treatment and tumor progression is almost ...

New targeted therapy schedule could keep melanoma at bay

March 26, 2018
Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for advanced melanoma has seen success with targeted therapies ...

Mathematical modeling offers new way to understand variable responses to targeted therapy

April 3, 2018
Cancer therapies that target a specific protein have improved outcomes for patients. However, many patients eventually develop resistance to these targeted therapies and their cancer comes back. It is believed that differences ...

Tumor-infiltrating B lymphocytes promote melanoma progression and resistance to therapy

September 19, 2017
In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells ("TABs") in melanoma ...

Arthritis drug could help treat advanced skin cancer

December 19, 2017
Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown.

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.